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ABSTRACT 
The X–linked disease Barth syndrome (BTHS) is caused by mutations in TAZ; TAZ is the 
main determinant of the final acyl chain composition of the mitochondrial-specific 
phospholipid, cardiolipin. To date, a detailed characterization of endogenous TAZ has 
only been performed in yeast. Further, why a given BTHS-associated missense mutation 
impairs TAZ function has only been determined in a yeast model of this human disease. 
Presently, the detailed characterization of yeast tafazzin harboring individual BTHS 
mutations at evolutionarily conserved residues has identified seven distinct loss-of-
function mechanisms caused by patient-associated missense alleles. However, whether 
the biochemical consequences associated with individual mutations also occur in the 
context of human TAZ in a validated mammalian model has not been demonstrated. Here, 
utilizing newly established monoclonal antibodies capable of detecting endogenous TAZ, 
we demonstrate that mammalian TAZ, like its yeast counterpart, is localized to the 
mitochondrion where it adopts an extremely protease-resistant fold, associates non-
integrally with intermembrane space-facing membranes and assembles in a range of 
complexes. Even though multiple isoforms are expressed at the mRNA level, only a 
single polypeptide that co-migrates with the human isoform lacking exon 5 is expressed 
in human skin fibroblasts, HEK293 cells, and murine heart and liver mitochondria. 
Finally, using a new genome-edited mammalian BTHS cell culture model, we 
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demonstrate that the loss-of-function mechanisms for two BTHS alleles that represent 
two of the seven functional classes of BTHS mutation as originally defined in yeast, are 
the same when modeled in human TAZ.   
INTRODUCTION 
The boundaries of cells and organelles are marked by membranes that differ in 
their phospholipid and protein compositions. The collection of phospholipids, including 
their associated fatty acyl chains, that establish a defined membrane-bound compartment 
confer unique membrane properties (curvature and rigidity) and contribute to numerous 
functions that occur at/across the membrane surface (transport and signaling) or within 
the space that it confines. As such, changes in membrane lipid composition can directly 
impact numerous fundamental cellular processes. A particularly salient example of the 
importance of proper lipid composition for organelle function is provided by the 
mitochondrion, the powerhouse of the cell, and its signature phospholipid, cardiolipin 
(CL).  
CL is required for a diversity of basic processes that are central to mitochondrial 
biology (1). In fact, CL is of such fundamental importance that mammalian development 
fails in utero in its absence (2). CL is a dimer of two phosphatidic acids linked together 
by a glycerol bridge. CL associates with numerous mitochondrial proteins, including 
every oxidative phosphorylation (OXPHOS) complex/component, many solute carriers, 
and translocases in both the outer and inner mitochondrial membranes (3-5). Collectively, 
these interactions with CL stabilize individual proteins and multisubunit complexes, and 
can stimulate enzyme activity either directly (e.g. serve a catalytic function (6)) or 
4 
secondarily (e.g. promote the assembly of individual respiratory complexes into more 
efficient supercomplexes (7-9)). Finally, CL serves as a signal that is detected by CL-
binding proteins with downstream consequences that range from mitochondrial fission 
and inner mitochondrial membrane (IMM) fusion (10, 11) to apoptosis and mitophagy 
(12, 13).  
The biosynthesis of CL occurs through a reaction series that is highly conserved 
from yeast to humans (14). With respect to its acyl chain composition, the CL that is 
newly produced is not what accumulates at steady state, which is highly homogeneous 
and characterized by increased acyl chain unsaturation and molecular symmetry (15). The 
steady state form of CL is established by an acyl chain remodeling process that begins 
with the removal of a fatty acyl chain from CL by a deacylase(s), generating 
monolysocardiolipin (MLCL), which is then re-acylated by the evolutionarily conserved 
MLCL transacylase, tafazzin (TAZ) (16). Mutations in TAZ result in the X-linked cardio- 
and skeletal myopathy, Barth syndrome (BTHS) (17, 18). In the absence of TAZ, there is 
less CL, the remodeling precursor and product, and more MLCL, the remodeling 
intermediate (19). Further, the CL that remains has an abnormal acyl chain profile (15,
20). These BTHS-associated changes in mitochondrial phospholipid composition 
destabilize respiratory supercomplexes, reduce OXPHOS efficiency, increase reactive 
oxygen species production, and impair sarcomere organization (21-24).  
BTHS is the founding member of a new class of mitochondrial disorder that 
results from nuclear defects that impact mitochondrial phospholipid metabolism (25).
Notably, some of the disorders, including dilated cardiomyopathy with ataxia (DCMA),
Sengers, and MEGDEL syndromes, in this new class of mitochondrial disease share some 
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biochemical phenotypes with BTHS. In each case, changes in the acyl chain pattern, 
abundance, and or submitochondrial distribution of CL are postulated to contribute to 
disease pathogenesis (26-29). However, their exact pathogenic mechanisms have not 
been established and thus the basis for the shared and unique phenotypes of this cohort of 
syndromes is presently unclear.  
Currently, a detailed topological map of tafazzin-based CL remodeling has only 
been drawn in the yeast Saccharomyces cerevisiae. In yeast, all of the steps up to and 
including the initiation of the remodeling process occur on the matrix side of the IMM 
(14). In contrast, yeast Taz1 is anchored to both the IMM and outer mitochondrial 
membrane (OMM) facing the intermembrane space (IMS) by virtue of a membrane 
anchor that protrudes into but not completely through the lipid bilayer (30). Thus, in yeast,
CL remodeling involves an obligate trafficking step of MLCL from one side of the IMM 
to the other. Further, a yeast BTHS model has been exploited to determine the disease 
pathogenicity of a multitude of patient-associated missense alleles. To date, seven distinct 
pathogenic loss-of-function (LOF) mechanisms have been identified (30-32). Thus at 
present, our understanding of the basic cell biology of this clinically important 
remodeling pathway and the biochemical abnormalities associated with any genetic 
lesion linked to BTHS is based solely on work in yeast.   
Here, we show that mammalian TAZ is localized to the mitochondrion where it 
adopts an extremely protease-resistant fold, associates non-integrally with IMS-facing 
membranes, and assembles in a range of complexes. Even though multiple isoforms are 
expressed at the transcript level, only a single TAZ polypeptide that co-migrates with the 
human isoform lacking exon 5 is detected in mitochondria isolated from human skin 
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fibroblasts, HEK293 cells, and murine heart and liver. Utilizing a newly established 
mammalian BTHS cell model, we determined that the two pathogenic mutations tested 
result in the same biochemical consequences when modeled in human TAZ as originally 
defined in yeast. Interestingly, overexpression of the unstable R57L mutant which lacks 
transacylase activity in vitro, partially rescues the mitochondrial CL and MLCL 
abnormalities of the taz deficient cells in vivo, suggesting that strategies aimed at
stabilizing this mutant allele could be of therapeutic benefit. 
RESULTS 
Mammalian TAZ is localized to the mitochondrion 
The absence of antibodies capable of detecting endogenous TAZ has significantly 
impeded progress in our understanding of BTHS pathogenesis. To overcome this obstacle, 
three TAZ-specific mouse monoclonal antibodies (mAb; 2G3F7, 3D7F11, and 2C2C9) 
were generated. Critically, each mAb detected endogenous TAZ in fibroblast cell extracts 
from healthy controls (C109) but not two BTHS patients (TAZ001 and TAZ003) (Fig.
1A). TAZ001 encodes a truncated 50 amino acid protein while TAZ003 has a single 
R57L missense allele in TAZ (20). Using these new reagents, endogenous TAZ co-
fractionated with mitochondria (Fig. 1B) and was detected in both human and murine 
mitochondria (Fig. 1C). 
Human TAZ mRNA is present as a number of splice variants (20, 33). To 
determine the capacity of the three mAbs to detect different TAZ isoforms, the epitope 
recognized by each mAb was mapped; each of the three mAbs binds an epitope that is 
present in a different exon (Fig. 1D). Moreover, they each have the capacity to recognize 
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every predicted isoform based on mRNA analyses (20, 33). Following 
immunoprecipitation of TAZ with one mAb (3D7F11), only a single TAZ band was 
detected by immunoblot using a second mAb (2C2C9) in control but not BTHS cell 
extracts (Fig. 1E). Finally, based on co-migration with assorted human TAZ isoforms 
expressed in taz1Δ yeast (34), all of the cells and tissues surveyed only express TAZ 
lacking exon 5 (TAZ-ex5; exon 5 is missing in rodents so full-length murine TAZ already 
lacks exon 5) (Fig. 1F). Thus, TAZ-ex5 is likely the major isoform expressed at the 
protein level in vivo. 
Generation of a mammalian BTHS cell model 
To establish a new mammalian BTHS cell culture model, we utilized TALEN-
mediated genome editing in 293 Flp-In cells to introduce genetic lesions within TAZ exon
1. Two tazTALEN clones were identified that had undetectable levels of TAZ protein (Fig. 
2B) and which contained genomic deletions in the targeted locus (Fig. 2A). In both
tazTALEN.2 and 19, a proline that is highly conserved in mammals but not in fungi, is 
deleted (Fig. S1); in addition, there was a missense mutation (V12A) identified in 
tazTALEN.19 and five additional amino acids removed (amino acids 11-16) in tazTALEN.2. 
Surprisingly, neither deletion altered the overall reading frame of TAZ. Based on in silico 
analyses (Table SI), we hypothesize that Pro13 is either a critical determinant of a non-
bilayer spanning membrane anchor and/or essential for TAZ folding and stability. 
Consistent with these possibilities, proteosomal inhibition with MG132 did not stabilize 
TAZ in either tazTALEN cell line (Fig. 2C). The lack of protein expression did not reflect 
differences in TAZ mRNA levels (Fig. 2D). Moreover, the expression of representative 
proteins of each mitochondrial subcompartment and every OXPHOS complex was the 
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same in mitochondria isolated from each tazTALEN cell line as WT (Fig. 2E and F). Of 
note, the expression of PHB2 and DNAJC19, proteins functionally linked to TAZ (28), 
was also not altered in either tazTALEN cell line. Finally, as matrix-targeted Su9-DHFR 
was imported into mitochondria isolated from both tazTALEN cells at rates similar to that 
of WT mitochondria, the membrane potential across the IMM is not grossly impaired in 
the tazTALEN cells (Fig. 2G and H).
 Next, the phospholipid composition of mitochondria isolated from WT and 
tazTALEN cells was determined by mass spectrometry. An increased MLCL:CL ratio is a 
biochemical hallmark of TAZ deficiency (35). Importantly, mitochondria from each 
tazTALEN cell contained a significantly increased MLCL:CL ratio (Fig. 3C) that was 
largely driven by an accumulation of MLCL (Fig. 3B). The amount of CL was not 
significantly changed (Fig. 3A). TAZ-based CL remodeling is a major determinant of the 
final acyl chain composition of CL at the steady state, which is typified by the inclusion 
of more unsaturated acyl chains compared to pre-remodeled CL. While there were only 
modest changes in CL acyl chain length in the tazTALEN cells (Fig. 3E), the amount of CL 
containing fewer double bonds was significantly increased (Fig. 3F). Moreover, the 
relative abundance of unsaturated acyl chains for CL molecules of a given length was 
consistently lower in tazTALEN than in WT mitochondria (Fig. 3G-K). In addition to its 
dramatically increased abundance, there were also notable changes in the acyl chain 
profile of the remodeling intermediate MLCL in mitochondria isolated from both 
tazTALEN cells (Fig. 3L-O). Specifically, MLCL with longer acyl chains that contained 
fewer double bonds accumulated in the absence of TAZ activity. Other alterations in the 
mitochondrial lipidome that were consistent features of mitochondria from both tazTALEN
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cells included an increased abundance of phosphatidylglycerol (PG, Fig. 3D), bis-
monoacylglyerol phosphate, reduced levels of phosphatidylinositol, and subtle changes in 
the acyl chain length and saturation of phosphatidylcholine (PC) and 
phosphatidylethanolamine, two lipid classes that can be used by TAZ as acyl chain 
donors for MLCL re-acylation (16) (Fig. S2-S4). Collectively, these results validate the 
tazTALEN cells as new cellular BTHS models.
Mammalian TAZ is a membrane protein that assembles in high molecular weight 
complexes 
Yeast Taz1 associates with the IMS-side of the IMM and OMM by virtue of a 
membrane anchor that extends into but not through the lipid bilayer (30). To determine if 
human TAZ is similarly membrane-associated, mitochondrial extracts from 293 Flp-In or 
C109 fibroblasts were sonicated and centrifuged to obtain the pellet, containing 
membrane-associated proteins, and the supernatant, containing soluble proteins. TAZ, 
like TIM23 and TOM20, was detected in the pellet fraction (Fig. 4A). Next, alkali 
extraction was performed. As expected, the integral proteins TIM23 and TOM20 were 
largely retained in the pellet whereas the peripheral cytochrome c (CYT C) was
quantitatively released into the supernatant (Fig. 4B). Like yeast Taz1, human TAZ was 
steadily released into the supernatant as the pH increased, suggesting a similar mode of 
membrane association (Fig. 4C). Alternatively, analogous to succinate dehydrogenase 
subunit A (SDHA), TAZ membrane association may be determined by an interaction 
with a yet-to-be identified integral membrane protein.  
As yeast Taz1 engages in a range of macromolecular complexes (30, 36), the
assembly of mammalian TAZ was examined by 2D blue native (BN)/SDS-PAGE. In
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both human and murine mitochondria, TAZ assembled in a range of complexes (Fig. 4D). 
In sum, these results demonstrate that mammalian TAZ associates with mitochondrial 
membranes and engages in macromolecular complexes in a manner that is highly 
reminiscent of its yeast ortholog.  
Mammalian TAZ is highly protease resistant and localized to IMS-facing leaflets 
Next, we determined the submitochondrial localization of TAZ. First, 
mitochondria from 293 Flp-In cells were titrated with increasing amounts of digitonin,
causing the sequential release of soluble IMS proteins, soluble matrix proteins, 
membrane proteins of the OMM, and finally IMM-embedded proteins into the 
supernatant (Fig. 5A and B). The fractionation profile of human TAZ overlapped with 
both IMM and OMM proteins (Fig. 5B) suggesting that like yeast Taz1, human TAZ may 
associate with both the IMM and OMM (4, 30, 37).
Second, a protease-protection assay was performed to determine if human TAZ is 
associated with IMS-facing membranes as predicted based on results in yeast. In brief, 
human and murine mitochondria were incubated in iso-osmotic buffer, low osmotic 
buffer, or low osmotic buffer supplemented with detergent, with each permutation 
performed in the absence or presence of the non-specific protease mixture, pronase E (Fig. 
5C). Accordingly, OMM proteins facing the cytosol (e.g. TOM20) are accessible to 
added protease in each condition, residents of the IMS (TIM23; TIM23 is an IMM 
protein with a large domain exposed to the IMS) are degraded by added protease 
following osmotic rupture of the OMM (low osmotic buffer) and detergent solubilization, 
and matrix proteins (GRP75) are only degraded upon addition of detergent with protease. 
Like the matrix marker GRP75, in every source of mitochondria tested, mammalian TAZ 
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was only degraded by pronase after detergent solubilization. These results thus suggest 
that mammalian TAZ is localized to the matrix-facing leaflet of the IMM, the opposite 
side of the IMM as yeast Taz1.  
This conclusion, however, is predicated on TAZ being sensitive to protease. Thus, 
another potential explanation for the observed pattern is that perhaps TAZ adopts a 
highly protease-resistant fold that becomes accessible to proteolytic cleavage only in the 
presence of detergent. To test the idea that TAZ is protease-resistant, we compared its 
sensitivity to proteases upon addition of detergent with or without prior heat denaturation 
(Fig. 5D). When solubilized with SDS, heat denaturation increased the sensitivity of TAZ 
to degradation by each protease. One potential explanation for the resistance of TAZ to 
proteolytic degradation is that it forms aggregates. However, using a sequential detergent 
solubility assay where TAZ was readily solubilized with digitonin (protein aggregates 
resist solubilization even when re-extracted with TX-100), TAZ does not form protein 
aggregates (Fig. 5E).  
In light of TAZ’s protease resistance, the assays performed cannot conclusively 
establish the topology of membrane-associated TAZ. Therefore, we performed an in
organello import assay in which radiolabeled TAZ precursor was incubated with WT 
mitochondria in the presence or absence of a membrane potential and non-imported 
precursor removed with trypsin (Fig. 5F). Import of TAZ was time-dependent but 
membrane potential-independent. The TAZ precursor was not processed upon import 
consistent with the failure of most in silico programs (Table SII) to predict a 
mitochondrial presequence cleavage site. Critically, 35S-TAZ precursor was readily 
degraded by trypsin following incubation with mitochondria on ice and disruption of the 
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OMM (compare lanes 7 and 8). Finally, following import in the presence of a membrane 
potential, disruption of the OMM in the presence of trypsin drastically decreased the 35S-
TAZ detected (lane 6). Thus, the protease resistance of TAZ observed at steady state 
occurs after it is imported into the mitochondrial IMS. 
To gain further insight into the topology of TAZ, epitopes tags were added to 
either termini of TAZ (CNAP-TAZ and TAZ-3XFLAG for NH2- or COOH-terminal 
tagged TAZ, respectively) (Fig. 6A). Upon transfection into the tazTALEN.19 cell line, 
each construct was expressed similar to untagged WT TAZ (Fig. 6B) and importantly, 
rescued the altered MLCL:CL ratio of this TAZ-deficient model (Fig. 6C and D). The
sensitivity of the appended epitope tags to proteolytic degradation was determined in 
intact mitochondria, following OMM rupture, or in the presence of detergent. Like the 
IMS marker TIM23, which is anchored to the IMM but exposes a large domain in the 
IMS, the NH2-terminal epitope of CNAP-TAZ became sensitive to added protease when 
the OMM was disrupted (Fig. 6F). In contrast, 3XFLAG added to the COOH terminus of 
TAZ was resistant to proteolytic degradation unless detergent was included (Fig. 6F). 
Thus, either the COOH terminus of TAZ is in the matrix, implying that TAZ has a 
membrane-spanning domain contrary to expectations based on its alkali extraction profile 
(Fig. 4B and C), or alternatively, the added tag is incorporated in the core protease-
resistant structure of TAZ. To distinguish between these two possibilities, we transfected 
the tazTALEN.19 cell line with TAZ harboring a COOH-terminal APEX2 tag (38, 39). 
APEX2 encodes an engineered ascorbate peroxidase that can be used in electron 
microscopy studies to localize a tagged protein (38, 39). TAZ-APEX2 was expressed 
normally and functional based on the restored MLCL:CL ratio (Fig. 6B-D). When 
13 
tazTALEN.19 cells expressing TAZ-APEX2 were reacted with 3,3’-diaminobenzidine 
(DAB), in the presence of H2O2, , electron micrographs revealed reaction product in and 
around the mitochondrial IMS (Fig. 6G). Conversely, DAB staining of tazTALEN cells 
expressing untagged TAZ (control) revealed no staining of the IMS. Our combined 
results indicate that mammalian TAZ adopts a highly protease-resistant structure 
following its import into the mitochondrial IMS where it non-integrally associates with 
mitochondrial membranes with both termini exposed to the IMS.  
The R57L allele encodes an unstable protein 
TAZ003 fibroblasts harbor an R57L missense mutation that was previously 
classified in yeast (K65L) as a temperature-sensitive allele (Fig. 7A) (20, 32). As such, 
the inability to detect TAZ in TAZ003 cells could provide evidence that like in yeast, the 
R57L allele is intrinsically unstable. To determine if the R57L allele encodes an unstable 
polypeptide, we re-introduced into the two tazTALEN cell lines WT TAZ, R57L, and an 
H69Q TAZ mutant that in yeast encodes a catalytically-null polypeptide (32). The 5-6 
subclones that were isolated per construct per parental cell line displayed little variability 
in TAZ expression for a given TAZ allele (Fig. 7B). Consistent with the possibility that 
the R57L allele is intrinsically unstable, its steady state expression in clones from both 
tazTALEN cells was dramatically reduced compared to WT TAZ-expressing cells. The
reduced expression was not reflected at the transcript level (Fig. 7C), did not result from 
impaired import into the mitochondrial IMS (Fig. 7D), and was not restored upon 
proteosomal inhibition (Fig. 7E and S5A). Moreover, when cytosolic protein synthesis
was inhibited with cycloheximide, R57L had a much shorter half-life (t1/2) than WT TAZ 
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(Fig. 7F and S5B). Thus, as previously characterized in a yeast BTHS model (32), the 
R57L BTHS variant encodes an unstable protein. 
The H69Q allele is catalytically-null 
The H69Q mutation disrupts a highly conserved HXXXXD acyltransferase motif. 
When modeled in yeast, the equivalent H77Q mutation results in a protein that behaves 
biochemically and cell biologically like WT Taz1 but that is completely devoid of 
transacylase activity (32). As expected, expression of H69Q in whole cell extracts (Fig.
7B) and isolated mitochondria (Fig. 8A) was similar to WT TAZ. The H69Q allele was 
imported into the mitochondrial IMS (Fig. 8B) and assembled in complexes (Fig. 8C and 
S5C) just like WT TAZ. The preserved complex formation of the H69Q mutant indicates 
that TAZ assembly is insensitive to increased MLCL or changes in CL acylation. To 
directly measure the transacylase activity of WT and mutant TAZ, isolated mitochondria 
were incubated with 14C-labeled lyso-PC and its conversion to PC monitored (Fig. 8D).
Overexpression of WT TAZ resulted in dramatically increased transacylase activity. In 
stark contrast, mitochondria overexpressing H69Q (or R57L) lacked any detectable 
transacylase activity above background. Finally, while WT TAZ restored the MLCL:CL 
ratio of both tazTALEN cell lines to normal, overexpression of the H69Q mutant did not 
(Fig. 8E-G). Therefore, the H69Q variant encodes a catalytically inactive polypeptide in 
both mammals and yeast. Intriguingly, overexpression of the R57L mutant, which was 
devoid of transacylase activity in vitro (Fig. 8D) did partially improve the MLCL:CL 
ratio of both tazTALEN cell lines in vivo (Fig. 8E-G) indicating that prior to its degradation, 
it retained some residual catalytic activity. Consistently, the R57L allele was still 
assembled normally (Fig. S5C). Collectively, these results suggest that the LOF 
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mechanisms that underlie certain missense mutations are conserved in yeast and 
mammalian BTHS models.  
DISCUSSION 
We have determined that CL remodeling is organized in topologically similar 
ways in mammals and yeast. Like in yeast, mammalian TAZ is localized to the IMS-
facing leaflets of the OMM and IMM. Thus, the main determinant of the final CL acyl 
chain pattern, TAZ, resides on the opposite side of the IMM as the CL biosynthetic 
machinery. In yeast, the lipase that functions upstream of Taz1, Cld1, is peripherally 
associated with the matrix side of the IMM (40). At present, the identity and detailed 
localization of the mammalian lipase(s) that functions upstream of human TAZ to initiate 
CL remodeling has not been defined. The rationale for the localization and topology of 
TAZ-based CL remodeling in yeast and mammals is presently unclear but is presumed to 
be important for it to function properly. Notably, besides dictating the final acyl chain 
pattern of CL, the physiological functions of this conserved remodeling pathway remain 
elusive (41). 
Overall, our work suggests that human and yeast TAZ, whose polypeptides are 
only 18% identical and 41% conserved, are remarkably similar biochemically. Not only 
are their submitochondrial localizations the same, yeast and mammalian TAZ also 
interact with mitochondrial membranes in a similar manner which in yeast involves a 
membrane anchor that extends into but not completely through the lipid bilayer (30).
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Further, both yeast and mammalian TAZ assemble in a range of complexes that appear 
qualitatively quite comparable (36). Previously, we demonstrated that yeast Taz1 does 
not associate with itself but does interact with the ATP synthase as well as the major 
mitochondrial ADP/ATP carrier, Aac2 (36). Thus, it is possible that these interactions 
will be evolutionarily conserved. However, it is important to mention that the vast 
majority of the yeast Taz1 interactome remains undocumented and the noted interactions 
between yeast Taz1 and the ATP synthase or Aac2 are clearly sub-stoichiometric. The 
composition of all of the mammalian TAZ-associated complexes is similarly unknown 
but is something we are actively investigating.  
Critically, another feature shared between yeast and mammalian TAZ are the LOF 
mechanisms associated with distinct pathogenic mutations. Using a novel BTHS cell 
model, the LOF mechanism for the two tested pathogenic mutations were conserved as 
modeled in yeast or human TAZ. In patient-derived TAZ003 cells, the protein product of 
the R57L allele is undetectable. When overexpressed in tazTALEN cells, the R57L mutant 
localized properly and assembled normally (Fig. S5A-C), but accumulated to a much 
lesser extent and had a significantly shorter half-life than WT TAZ. The corresponding 
yeast mutant, K65L, is a temperature-sensitive allele that becomes unstable and loses 
activity at non-permissive temperature (32). Interestingly, even though the R57L allele 
lacked in vitro activity, its overexpression did improve the MLCL:CL ratio in both 
tazTALEN cells (Fig. 7G). Therefore, small molecules capable of stabilizing the R57L 
mutant could increase its activity and thus represent viable therapeutic options.
Importantly, dysfunctional conservation extends to the H69Q mutation. In yeast, the 
corresponding H77Q mutant is identical to WT Taz1 in every way tested except that it is 
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devoid of transacylase activity (32). As predicted from yeast, the H69Q mutant allele 
closely resembled WT TAZ except that it was catalytically-null. 
TAZ is a promiscuous transacylase that can utilize a range of lyso-lipid substrates 
and phospholipid acyl chain donors. Moreover, TAZ itself lacks intrinsic acyl chain 
specificity which raises the obvious question of how a non-specific enzyme can generate 
CL that typically has a specific collection of acyl chains. Recent experiments have 
suggested that the physical state of phospholipid membranes can affect the substrate 
specificity of TAZ. Under experimental conditions that mimic high membrane curvature,
have an increased proportion of non-bilayer lipids, or perturbed bilayer states, TAZ gains
the capacity to generate the physiologically-relevant CL molecular form that contains 
four attached 18:2 linoleic acids (42). In mitochondria, such privileged lipid domains may 
be delineated by the recently described prohibitin/DNAJC19 complexes (28). The ring-
shaped prohibitin complexes, composed of PHB1 and PHB2 subunits and including 
DNAJC19 (28), form protein and lipid scaffolds within the IMM that contribute to cristae 
morphogenesis and cell proliferation (43). Surprisingly, knockdown of either PHB2 or 
DNAJC19, which do not interact with TAZ, changes the acyl chain pattern of CL similar 
to TAZ depletion (28). Depletion of either protein with TAZ does not prevent the 
accumulation of MLCL. These findings suggest that PHB/DNAJC19 complexes 
participate in CL remodeling after the process is initiated. Since MLCL does not 
accumulate, TAZ is still active when PHB2 or DNAJC19 expression is reduced. 
Although both completely traverse the IMM bilayer, the majority of the DNAJC19 
polypeptide resides in the matrix. Thus, how PHB/DNAJC19 complexes could modulate 
TAZ specificity remains unclear based on the submitochondrial localization and 
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interfacial membrane association of TAZ as defined previously in yeast and here in 
mammals. Given our placement of mammalian TAZ on the IMS-leaflet of the IMM, it is 
tempting to speculate that PHB/DNAJC19 complexes sequester TAZ within membrane 
domains with physical properties (high membrane curvature) that confer acyl chain 
specificity to TAZ. While the exact details of how PHB/DNAJC19 complexes modulate 
the specificity of TAZ-mediated CL remodeling is undefined, the functional relationship 
between PHB/DNAJC19 complexes and TAZ is underscored by the fact that mutations in 
DNAJC19 result in DCMA, a disease that shares many clinical features with BTHS (25, 
26). Our results thus establish a framework to dissect the functional relationship between 
PHB/DNAJC19 complexes and TAZ which may in turn reveal the basis for the shared 
and distinct phenotypes of BTHS and DCMA. 
  
MATERIALS AND METHODS 
Molecular Biology — The human TAZ ORF lacking exon 5 was amplified by PCR 
using cDNA from HeLa cells and subcloned first into pBSK (Stratagene) and then into 
pcDNA5/FRT (Invitrogen). The R57L and H69Q mutations were introduced into the 
parental pcDNA5/FRThTAZ plasmid via overlap extension (44). TAZ with an NH2
terminal CNAP tag (45) or COOH terminal 3XFLAG or APEX2 tags were introduced 
into the parental pcDNA5/FRThTAZ plasmid via overlap extension (44). For 
TAZAPEX2, pcDNA3APEX2-NES (39), a gift from Alice Ting (Addgene plasmid # 
49386), was used as template. For in vitro transcription/translation, WT TAZ and the 
R57L and H69Q alleles were subcloned into pSP64. The sequence of every construct was 
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verified by DNA sequencing. The TALEN binding pair recognizes sequences in TAZ
exon1 that are separated by 16 nucleotides and immediately downstream of the start site 
(Life Technologies). The two constructs, which are fused to the truncated Fok1 nuclease, 
were subcloned into pcDNA3.1 and pEF6/V5-HisA (Life Technologies) generating 
pcDNA3TAZ1-R and pEF6ATAZ1-L, respectively.
Cell Culture — All cells were grown at 37°C, 5% CO2. Control (C109) and BTHS 
patient fibroblasts (TAZ001 and TAZ003) (20) were maintained in DMEM (Cellgro) 
containing 10% fetal bovine serum (FBS, Hyclone), 2 mM L-glutamine (Gibco), and 50 
units/L penicillin-streptomycin (Gibco). HEK293 Flp-In cells (Invitrogen) were grown in
DMEM containing 10% FBS, 2 mM L-glutamine, and 100 μg/ml zeocin (Invitrogen). To
establish a BTHS cell model, 293 Flp-In cells grown in medium lacking antibiotic but 
supplemented with 50 μg/ml uridine, were transfected with a 1:1 ratio of pCDNA3TAZ1-
R and pEF6ATAZ1-L using FuGENE 6 (Promega), selected with 0.5 mg/ml G418 and 5 
μg/ml blasticidinS (Cellgro) for 1 week, and single colonies isolated by ring cloning.
Individual clones were maintained in the same medium as used for the parental 293 Flp-
In cells and the inclusion of uridine found to not be essential. Whole cell extracts derived 
from candidate clones were harvested and analyzed by SDS-PAGE and immunoblot. 
Stable tazTALEN rescue cell lines were generated by co-transfecting the two tazTALEN cell 
lines with pOG44 (expressing the Flp-recombinase) and the relevant pcDNA5/FRT 
plasmid (WT, CNAP-TAZ, TAZ-3XFLAG, TAZ-APEX2, R57L, H69Q) at a ratio of 9:1
using FuGENE 6. Transfected cells were selected using 200 μg/ml hygromycin B 
(Invitrogen), individual clones recovered by ring cloning, expanded, and screened by
immunoblot. Equal numbers of individual clones per construct were combined to 
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establish a pooled clonal population that was then used in all subsequent analyses. Each 
pooled population was derived from at least 5 individual clones except for tazTALEN.19
overexpressing CNAP-TAZ which was established from 3 clones. Mycoplasma 
contamination was routinely monitored and not detected. 
Purification of recombinant human TAZ — The entire open reading frame of TAZ
lacking exon5 was cloned into the pET28a vector (Novagen) downstream of the 6xHis 
tag, induced at 37°C for 4 hours with 1 mM IPTG in C41 (DE3) Escherichia coli, and 
inclusion bodies separated from native protein extracts by centrifugation at 22,000 ×g for
1 hour at 4°C. Lipids and debris were removed from the inclusion bodies by resuspending 
the pellet with 7-10 mls of wash buffer (50 mM Tris-HCl, pH 7.0, 2.5 mM EDTA, 1 M 
urea, 1% (v/v) Triton X-100) per gram of cells using a dounce homogenizer followed by 
centrifugation at 22,000 ×g for 30 minutes at 4°C. This wash step was repeated three 
times until the supernatant was clear. A final wash was performed using wash buffer 
lacking urea and Triton X-100. The final recovered protein pellet was resuspended using 
a dounce homogenizer with 4 ml of extraction buffer (50 mM HEPES-KOH, pH 7.5, 5 
mM EDTA, 8 M guanidine-HCl, 2 mM β-mercaptoethanol) per gram of cells and 
clarified by centrifugation at 100,000 ×g for 1 hour at 4°C. The solubilized inclusion 
bodies were mixed 1:1 with ddH2O, His6-TAZ purified using Ni2+ agarose (Qiagen), and 
bound material recovered under denaturing conditions. 
Antibodies — Custom monoclonal antibodies against human TAZ-ex5 were produced 
by Genscript using purified recombinant protein as antigen. Three hybridomas – 2C2C9, 
3D7F11, and 2G3F7 – that secrete TAZ-reactive antibodies were established. Antibodies 
against the following proteins were: GRP75 (Antibodies Inc. 75-127); β-actin (A5441) 
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and TIMM9 (WH0026520M1) (Sigma); topoisomerase I (Developmental Studies 
Hybridoma Bank CPTC-TOP1-1-S); calreticulin 3 (sc-134295) and TOM20 (sc-11415) 
(Santa Cruz); HLA-B (Epitomics 2389-1); TIM23 (611332), CYCS (556433), 
SMAC/DIABLO (612246), and cyclin D1 (556470) (BD); UQCRC2 (ab14745), ACO2 
(ab129069), VDAC1 (ab15895), and COX4 (ab16056) (Abcam); SDHA (Invitrogen 
4592000); PHB2 (BioLegend 611802); DNAJC19 (ProteinTech 12096-1-AP); and 
NDUFB6 (Molecular Probes, discontinued). F1β was a kind gift from Dr. Peter Pedersen 
(Johns Hopkins School of Medicine) and the ANT2/5H7 (46) antibody was raised against 
the yeast ADP/ATP carrier, Aac2, but conveniently cross-reacts with human and murine 
ANT2. Goat anti-rabbit or mouse secondary antibodies conjugated to horseradish 
peroxidase were also used (31460 and 62-6520; Pierce).
Whole cell extraction — Confluent culture dishes were washed twice with ice-cold PBS 
and lysed with RIPA lysis buffer (1% (v/v) Triton X-100, 20 mM HEPES-KOH, pH 7.4, 
50 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, 0.1% (w/v) SDS) spiked with 1 mM PMSF 
for 30 minutes at 4°C with rotation. Insoluble material was removed by centrifugation for 
30 minutes at 21,000 ×g at 4°C, the supernatant collected, and protein quantified using a 
bichichronic acid (BCA) assay (Pierce). 
Immunoblotting — SDS-PAGE and immunoblotting was performed as previously 
described (47). Images were captured with a Fluorchem Q (Cell Biosciences, Inc) 
quantitative digital imaging system and quantitation performed using the indicated 
software. Images were processed in Adobe Photoshop with only linear adjustments in 
contrast and brightness and assembled in Adobe Illustrator. 
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Preparation of subcellular fractions — Fibroblasts and 293 Flp-In cells were seeded 
onto four 150 mm×25 mm tissue-culture dishes and allowed to expand to confluency. 
Two days prior to mitochondrial isolation, the cells were switched from dextrose- to
galactose-based media (DMEM without glucose, Gibco; supplemented with 10 mM 
galactose, Sigma). Mitochondria were isolated on ice (with ice-cold buffers) using a 
protocol adapted from (48). Briefly, after aspirating spent media from dishes, cells were 
scraped off in PBS and centrifuged at 600 ×g for 10 minutes. After washing the cells 
once more with PBS, the pelleted cells were resuspended in 3 ml isolation buffer (IBc, 10 
mM Tris-MOPS, 1 mM EGTA/Tris, pH 7.4, 200 mM sucrose) and homogenized with 40-
45 strokes in a motor-driven tightly fitting Teflon Potter-Elvehjem at 1,600 rpm. Cell 
lysates were then centrifuged twice at 600 ×g for 10 minutes; the resulting pellet is the 
nuclear fraction. Mitochondria were recovered from the supernatant by centrifugation at 
7,000 ×g for 10 minutes. The mitochondrial pellet was resuspended to a volume that fits 
a 1.5 ml microcentrifuge tube; after an additional 7,000 ×g spin, a 10,000 ×g clarifying 
spin was performed to obtain crude mitochondria. The supernatant from the prior 7,000 
×g spin contains cytosolic, lysosomal, and ER fractions which were further sub-
fractionated as follows. Lysosomes were pelleted after a 20,000 ×g spin for 30 minutes 
and resuspended in a residual amount of IBc. The remaining supernatant was centrifuged 
at 40,000 ×g for another 30 minutes to obtain plasma membranes. Further centrifugation 
of the obtained S40 (100,000 ×g for 1 hour) resulted in the isolation of ER (pellet) and 
cytosolic fractions (supernatant). Heart and liver mitochondria from 10-12 week old 
female FVB mice were isolated on ice using a protocol adapted from (49, 50). Briefly, 
tissues were rinsed with ice-cold CP1 (100 mM KCl, 50 mM MOPS, pH 7.4, 5 mM 
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MgSO4, 1 mM EGTA, 1 mM ATP), minced with scissors and washed several times with 
CP1 before resuspension in CP2 (CP1 supplemented with 2 mg/ml BSA). Tissues were 
then homogenized using a Polytron (three 2.5 second pulses on medium setting; Fisher 
PowerGen 1000 large bore homogenizer). The homogenate was centrifuged at 580 ×g for
7 minutes at 4°C and the resultant supernatant contained either liver mitochondria or in 
the case of heart tissue, subsarcolemmal mitochondria (SSM), while the pellet contained 
heart interfibrillar mitochondria (IFM). Liver and SSM supernatants were repeatedly 
centrifuged at 580 ×g until there were no visible cell/debris pelleting. A final clarifying 
spin at 3,000 ×g for 7 minutes was performed before resuspending the mitochondrial 
pellets in KME (100 mM KCl, 50 mM MOPS, 1 mM EGTA). To extract IFM 
mitochondria, the pellet was resuspended in CP1 containing 5 mg trypsin per gram tissue 
with mixing, for 10 minutes on ice. The trypsin was inactivated with an equivalent 
volume of CP2 before centrifugation at 7,500 ×g for 7 minutes at 4°C. For our purposes 
(to maximize heart mitochondrial yield) the resultant pellet was resuspended in CP2, 
clarified with a 3,000 ×g spin before being resuspended in KME and combined with the 
SSM mitochondria. Organellar and mitochondrial fractions were quantitated using a BCA 
assay. Mitochondria were resuspended to 10 mg/ml in IBc (cells) or KME (tissues) and if 
not used immediately, aliquoted, snap frozen with liquid N2, and stored at -80°C for 
downstream analyses. 
Epitope-Mapping — A peptide scan consisting of 15mer peptides with an 11 amino acid 
overlap between adjacent peptides that spans the entire 262 amino acid TAZ protein was
generated by JPT Peptide Technologies. The membrane was moistened with methanol 
prior to immunoblotting and the membrane subsequently regenerated with 100 mM β-
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mercaptoethanol, 1% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.7, two more times to map 
epitopes bound by the different TAZ monoclonal antibodies. The epitopes recognized by 
each of the three monoclonal antibodies were determined by densitometry analysis of the 
immunoreactive PepSpots. 
Immunoprecipitation — The TAZ monoclonal antibody, 3D7F11, or normal mouse 
serum was conjugated to protein G-sepharose using the Seize X Protein A 
Immunoprecipitation kit and protocol (Pierce). Confluent T75 cm2 flasks of the indicated 
cells were lysed with 1 ml RIPA lysis buffer and protein extracts quantified as described 
above. 1.5 mg cellular extract per cell line was diluted to 1 ml with protease inhibitor-
spiked lysis buffer and rotated with 90 μl normal mouse serum-conjugated beads for 1
hour at 4°C. After centrifugation at 376 ×g for 5 minutes at 4°C, the pre-cleared lysates 
were transferred to tubes containing 90 μl 3D7F11-conjugated beads and rotated at 4°C 
for 4 hours. Following low speed centrifugation as before, unbound extract was collected 
for analysis and the bound material (both the pre-clear and IP beads) was sequentially 
washed (10 minutes rotating per wash) twice with Wash Buffer (0.1% (v/v) Triton X-100, 
20 mM HEPES-KOH, pH 7.4, 50 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, 0.1% (w/v) 
SDS; 1 ml per wash), twice with High Salt Wash Buffer (0.1% (v/v) Triton X-100, 20 
mM HEPES-KOH, pH 7.4, 500 mM NaCl, 1 mM EDTA, 2.5 mM MgCl2, 0.05% (w/v) 
deoxycholate; 1 ml per wash) and once with Low Salt Wash Buffer (0.1% (v/v) Triton X-
100, 20 mM HEPES-KOH, pH 7.4, 1 mM EDTA, 2.5 mM MgCl2, 0.05% (w/v) 
deoxycholate; 1 ml per wash). To elute bound material, three sequential elutions were 
performed using 0.1 M glycine, pH 2.8, and the pooled eluates were neutralized with 50 
μl 1 M Tris-Cl, pH 8.0. Eluates were transferred to a spin column (Pierce 1824826) and 
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centrifuged for 2 minutes at 376 ×g to reduce resin carry-over. Finally, the unbound 
extracts (pre-clear and IP beads) and eluates were TCA-precipitated (20% (v/v) TCA 
with 0.07% (v/v) deoxycholate) for 1 hour on ice, the pellet fractions resuspended in a 
1:1 mix of 2X reducing sample buffer and 0.1 M NaOH, and boiled for 5 minutes. 
Genotyping tazTALEN cells — Genomic DNA was extracted using the Gentra Puregene 
Cell Kit (Qiagen) and the genomic region surrounding the target site (exon1 extending 
into exon2, encompassing the ATG) was PCR amplified, digested with XbaI/HindIII 
(NEB), and ligated into pBSK(-). Transformants were analyzed by Sanger sequencing. 
As 293 cells are hypotriploid, sequences of at least 10 individual clones for each of the 
two tazTALEN cell lines were obtained, revealing disruption of TAZ downstream of the 
initiation codon.  
Quantitative RT-PCR — Total RNA was isolated from WT, tazTALEN, and tazTALEN
overexpressing TAZ alleles using the PureLink RNA Mini Kit with DNase treatment 
(Invitrogen). 25 ng of RNA was analyzed in 20 μl reactions using the EXPRESS One-
Step SYBR GreenER qRT-PCR Kit (Life Technologies) with 7500 Real-Time PCR 
Systems (Applied Biosystems) according to the manufacturer’s instructions. Each 
reaction, including non-template controls, was performed at least in duplicate with a 
minimum of three different biological replicates and contained 50 nM ROX and 200 nM 
each of forward and reverse gene-specific primers designed with Primer3 (51). The 
reaction conditions were as follows: 5 minutes at 50°C, 2 minutes at 95°C, followed by 
40 two-temperature cycles (15 seconds at 95°C and 1 minute at 60°C) and melt curve 
profiling. Expression of TAZ was analyzed by the comparative CT (ΔΔCT) method 
(XTest/XGAPDH=2-ΔΔCT) with GAPDH as an endogenous reference gene. Values were 
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represented as mean ΔΔCT ± SEM or fold change (2ΔΔCT) ± SD relative to TAZ
expression in 293 Flp-In cells (Prism 6).
Import — Radiolabeled precursors were produced using an SP6 Quick Coupled 
Transcription/Translation system (Promega) spiked with Easy-Tag L-35S-methionine 
(PerkinElmer). Radiolabeled precursors were incubated in import buffer (20 mM 
HEPES-KOH, pH 7.4, 250 mM sucrose, 80 mM KOAc, 5 mM MgOAc, 10 mM 
succinate, and 5 mM methionine) with freshly isolated mitochondria for the indicated 
amount of time at 37°C or 4°C, as specified. To dissipate the mitochondrial proton-
motive force, mitochondria were pre-incubated with 1 μM valinomycin and 5 μM
carbonyl cyanide m-chlorophenyl hydrazine for 5 minutes at 37°C. Import was stopped 
with an equal volume of ice-cold import buffer containing 20 μg/ml trypsin. Where 
indicated, the OMM was ruptured as already described in the presence of 20 μg/ml 
trypsin. Following 30 minutes on ice, 100 μg/ml soybean trypsin inhibitor was added and 
mitochondria were re-isolated by centrifugation at 21,000 ×g for 5 minutes at 4°C. 100% 
of each time point and 5% of imported precursors were resolved on 12% SDS-PAGE gels 
and analyzed by phosphoimaging.
Lipidomics — A defined amount of internal standards (0.1 nmol of CL(14:0)4, 0.2 nmol 
of BMP(14:0)2, 2.0 nmol of PC(14:0)2, 0.1 nmol of PG(14:0)2, 5.0 nmol of PS(14:0)2, 0.5 
nmol of PE(14:0)2, 1.0 nmol of PA(14:0)2, 2.0 nmol of SM(14:0)2, 0.02 nmol of 
LPG(14:0), 0.1 nmol of LPE(14:0), 0.5 nmol of LPC(14:0), 0.1 nmol of LPA(14:0) 
(Avanti Polar Lipids) dissolved in 120 μl of chloroform/methanol (1:1, v/v)) and 1.5 ml 
of chloroform/methanol (1:1, v/v) were added to 1 mg mitochondria. Subsequently, the 
mixture was sonicated in a water bath for 5 minutes, followed by centrifugation at 15,000 
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×g for 5 minutes. The organic layer was transferred to a glass vial and dried under a 
nitrogen steam at 60°C. Subsequently, the residue was dissolved in 200 μl of 
chloroform/methanol/water (50:45:5, v/v/v) containing 0.01% of NH4OH, and 10 μl of 
the solution was injected into the liquid chromatography-mass spectrometry (LC/MS) 
system. LC/MS analysis was performed as described in (35). In negative mode, mass 
spectra of phospholipid molecular species were obtained by continuous scanning from 
m/z 380 to 1500 with a scan time of 2 seconds. In positive mode, mass spectra of PC, 
LPC and SM were obtained by continuous scanning for product ions with m/z 184 from 
m/z 400 to 1000. Mass spectra for PE, LPE and PE plasmalogens were obtained by 
scanning on neutral losses of 141 from m/z 400 to 1000. The raw LC/MS data were 
converted to mzXML format using msConvert (52) for the negative scan data and 
ReAdW for the positive specific scan data. Details on the metabolic data pre-processing 
pipeline will be described elsewhere (manuscript in preparation). Briefly, the dataset was 
processed using a semi-automated xcms-based metabolomics workflow (53) written in 
the R language and statistical environment (http://www.r-project.org/). The workflow 
comprises pre-processing (peak-finding and quantification), identification of metabolites, 
isotope correction, normalization/scaling based on internal added standards and statistical 
analysis of the results.
Membrane association assays — Sonication experiments utilized 0.2 mg mitochondria 
and were performed in the absence of KCl as described (40). The supernatant and 
membrane fractions were separated by ultracentrifugation at 175,000 ×g using a 
TLA120.1 rotor for 30 minutes at 4°C. Carbonate extraction was performed as described 
(30) except that 0.5 ml of 0.1 M Na2CO3 at the indicated pH was added to 0.1 mg 
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mitochondria, and following 30 minutes on ice, the pellet and supernatant fractions were 
separated by centrifugation at 175,000 ×g for 15 minutes at 4°C using a TLA120.1 rotor.
Blue native (BN) gel electrophoresis — Mitochondria were solubilized for 30 minutes 
on ice in 20 mM HEPES-KOH, 10% glycerol, 50 mM NaCl, 1 mM EDTA, 2.5 mM 
MgCl2, pH 7.4 supplemented with 1% (w/v) (mouse tissues) or 1.25 % (w/v) (human 
cells) digitonin (Biosynth International, Inc) and protease inhibitors. Extracts were 
clarified by centrifugation for 30 minutes at 21,000 ×g at 4°C and analyzed by 2D 
BN/SDS-PAGE exactly as described (45).
Digitonin fractionation assay — Digitonin-based submitochondrial localization was 
adapted from (40). In brief, 0.1 mg mitochondria were resuspended in 50 μl SEHK buffer 
(250 mM sucrose, 5 mM EDTA, pH 7.0, 10 mM HEPES-KOH, pH 7.4, 200 mM KCl) 
supplemented with 0-0.5% digitonin and 1 mM PMSF. Following a brief vortex on level 
1, samples were incubated for 2 minutes on ice and solubilization stopped by adding 450 
μl cold SEHK buffer. Solubilized proteins were separated from the membrane pellets by 
centrifugation at 100,000 ×g for 10 minutes at 4°C. After the supernatant was TCA-
precipitated, the membrane and supernatant-derived pellets were resuspended in equal 
volumes of reducing sample buffer. 
Protease-based assays — Freshly isolated mammalian mitochondria (0.2 mg) from cells 
or tissues were resuspended in iso-osmotic IBc or KME buffers, respectively. To rupture 
the OMM, mitochondria (0.2 mg) were resuspended in 5 mM Tris-Cl, pH 7.5 for 30 
minutes on ice; 0.5% (v/v) deoxycholate was added to further solubilize the IMM. Each 
of these conditions was performed in the absence and presence of 125 μg/ml pronase E. 
Pronase was inhibited with 5 mM PMSF and samples precipitated with 20% (v/v) TCA 
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and 0.07% (v/v) deoxycholate, incubated at 60°C for 5 minutes followed by an hour on 
ice. Samples were centrifuged at 21,000 ×g for 10 minutes at 4°C, washed with 1 ml of 
cold acetone, resuspended in a 1:1 mix of 2X reducing sample buffer:0.1M NaOH and 
boiled for 5 minutes. To determine sensitivity to assorted proteases following heat 
denaturation, mitochondria (0.2 mg) were resuspended in 5 mM Tris-Cl, pH 7.5 
containing 0.1% (v/v) SDS, kept on ice or incubated at 95oC for 5 minutes, and then 5 
mM Tris-Cl, pH 7.5 with 0.1% SDS containing 250 μg/ml pronase E, 200 μg/ml 
proteinase K, or 40 μg/ml trypsin added. Following a 30 minute incubation on ice, 
pronase E and proteinase K were inhibited with 5 mM PMSF and trypsin with 100 μg/ml 
soybean trypsin inhibitor. Every sample was precipitated with 20% (v/v) TCA and 0.07% 
(v/v) deoxycholate, incubated at 60°C for 5 minutes followed by an hour on ice. Samples 
were centrifuged at 21,000 ×g for 10 minutes at 4°C, washed with 1 ml of cold acetone, 
resuspended in a 1:1 mix of 2X reducing sample buffer:0.1M NaOH and boiled for 5 
minutes.  
Protein aggregation assay — Protein aggregation was determined in mitochondria (0.2 
mg) isolated from 293 Flp-In cells exactly as previously described (31).
Phospholipid labeling and analyses — Cells were seeded onto 60 mm dishes or 6 well 
plates and allowed to grow to 50-70% confluency at 37°C, 5% CO2. Following aspiration, 
regular media spiked with 2.5 μCi/ml 32Pi was added and the cells incubated at 37°C, 5% 
CO2 for 24 hrs. Cells were washed twice with ice cold 1X PBS, detached in 0.8 ml IBc
buffer using a cell scraper, transferred to a microfuge tube, collected at 600 ×g 5 min at 
4oC, and resuspended in 0.1 ml IBc buffer. Phospholipids were extracted from equal 
amounts of labeled cells, determined by liquid scintillation, as described (30) except that 
30 
0.9% (w/v) NaCl was used to initiate phase separation instead of ddH2O. Samples were 
resuspended in chloroform, loaded onto ADAMANT TLC plates (Machery-Nagel), 
resolved once in chloroform:ethanol:H2O:trimethylamine (30:35:7:35, v/v/v/v), and 
phospholipids visualized using a K-screen and FX-Imager (Bio-Rad Laboratories). 
Electron microscopy — Cells were seeded onto 100 mm dishes and allowed to grow to 
~70% confluence before fixing with 3.0% formaldehyde and 1.5% glutaraldehyde in 0.1 
M sodium cacodylate, 5 mM CaCl2, 2.5% (w/v) sucrose, pH 7.4, for 1 hour at RT. Cells 
were washed three times for 15 minutes each with 0.1 M sodium cacodylate, 2.5% (w/v) 
sucrose, pH 7.4, and another three times for 5 minutes each with 50 mM Tris-HCl, 7.5% 
(w/v) sucrose, pH 7.4, prior to labeling with 0.5 mg/mL DAB and 0.015% H2O2 in 50 
mM Tris-HCl, 7.5% (w/v) sucrose, pH 7.4 for 20 to 60 minutes. The labeling reaction 
was stopped by rinsing cells twice with 50 mM Tris-HCl, 7.5% (w/v) sucrose, pH 7.4, 
and once with 0.1 M sodium cacodylate, pH 7.4, 5 mM CaCl2, 2.5% (w/v) sucrose, 
before harvesting the cells with 1 ml of 0.1 mM cacodylate buffer, pH7.4; and pelleting 
the cells in 1.5 ml Eppendorf tube. Cells were pelleted progressively by spinning from 
3,000 rpm to 12,000 rpm over the course of 10 minutes and the pellet was post-fixed in 
reduced osmium tetroxide (1% OsO4, 1% potassium ferrocyanide in 0.1 M sodium 
cacodylate, 5 mM CaCl2, pH 7.4) for 45 minutes at RT. The pellets were washed 
thoroughly with 0.1 M sodium cacodylate, pH 7.4, 5 mM CaCl2, 2.5% (w/v) sucrose 
several times until solution becomes clear, dehydrated through a graded series of ice-cold 
ethanol, and subsequently embedded in Epon resin. Sections were cut on a Leica UCT
ultramicrotome and observed on an FEI Tecnai 12 transmission electron microscope at 
100 kV. Images were captured with a Soft Imaging System Megaview III digital camera 
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and figures were assembled in Adobe Photoshop and Illustrator with only linear 
adjustments in contrast and brightness.
Cycloheximide chase — Cell culture medium lacking antibiotics but containing 100
μg/ml cycloheximide was added to confluent 6-well plates and incubated at 37°C, 5% 
CO2. At the designated times, cells were solubilized with 100 μl 1% (w/v) SDS and 
diluted to 0.5% SDS, 1% β-mercaptoethanol with 2% (v/v) β-mercaptoethanol. After 
denaturing the lysates at 100°C for 10 minutes, protein was quantified using the Bradford 
method (Bio-Rad).
Transacylation assay — The transacylase assays were performed as previously described 
(16, 32) using 1 nmol of 1-[14C]palmitoyl-2-lyso-PC (0.05 mCi; PerkinElmerLife 
Sciences) per reaction in 0.2 ml reaction buffer (10 mM β-mercaptoethanol, 0.5 mM 
EDTA, 50 mM Tris, pH 7.4). To initiate the reactions, ~125 μg mitochondria (the exact 
amount was determined by the BCA assay) were added, the reactions vortexed on high 
for 1 second, and incubated with shaking at 220 rpm for 5 minutes at 37°C. Lipid 
extraction, thin layer chromatography separation, image acquisition and analyses were 
executed as described (32).
Data analysis — Band densitometry analyses were performed using Quantity One (Bio-
Rad) or Image J (54). With the exception of the data in Fig 2D and 7D, statistical 
analyses were performed using SigmaPlot 11 software (Systat Software) and all 
comparisons performed by t test or one-way analysis of variance with Holm-Sidak 
pairwise comparisons. For Fig 2D and 7D, comparisons were performed using one-way 
analysis of variance with Geisser-Greenhouse correction Tukey’s multiple comparison 
test available in the Prism 6 software (GraphPad). All graphs report the mean ± SEM.
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LEGENDS TO FIGURES 
Figure 1. One isoform of TAZ is expressed and localized to mitochondria in 
mammalian cells and tissues. (A) Whole cell extracts (50 μg) from healthy control 
(C109) and BTHS patient fibroblasts (TAZ001 and TAZ003) were immunoblotted with 
three different mAbs generated against recombinant human TAZ. (B) Subcellular 
fractions (50 μg) derived from C109 cells immunoblotted as indicated. (C) Mitochondrial 
extracts (50 μg) from the indicated source immunoblotted with the TAZ mAbs. (D) The
epitope recognized by each TAZ mAb was determined by peptide array. The exon that 
harbors each epitope is indicated. (E) TAZ was immunoprecipitated with 3D7F11 from 
1.5 mg of the indicated cell extracts. 50 μg starting material and non-binding flow 
through and 100% of bound material (Preclear and IP) were immunoblotted using 2C2C9. 
(F) Whole cell extracts from WT or taz1Δ yeast transformed as indicated and 
mitochondrial extracts from the designated source immunoblotted for TAZ. EV, empty 
vector. *, nonspecific band. 
Figure 2. Generation of a BTHS cell culture model using TALEN-mediated genome 
editing. (A) TALEN-mediated disruption of TAZ in 293 Flp-In cells introduces 
nucleotide deletions that result in an in-frame deletion in tazTALEN.2 and a missense and 
in-frame deletion in tazTALEN.19. (B) Whole cell extracts from the indicated cells grown 
in dextrose or galactose-based media were resolved by SDS-PAGE and immunoblotted. 
(C) WT 293 Flp-In and tazTALEN cells were incubated for 4 hours with 20 μM of the 
proteasome inhibitor, MG132. 40 μg of whole cell lysates were resolved by SDS-PAGE 
and immunoblotted for the indicated proteins. Cyclin D1, a target of the ubiquitin-
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proteasome pathway (55), is used as a positive control. (D) Relative mRNA level of TAZ
in WT (293 Flp-In) and each tazTALEN cell. Data was analyzed by the comparative CT
(ΔΔCT) method, represented as mean ΔΔCT ± SEM n = 8 relative to WT expression level, 
which was set to 0. (E) Mitochondria (50 μg) from the designated source were 
immunoblotted as listed. (F) Protein expression in (E) was quantified by densitometry 
and normalized to WT levels (mean ± SEM; n = 3). Significant differences are indicated. 
(G) In organello import of radiolabeled [35S]-Su9-DHFR into WT 293 Flp-In and 
tazTALEN mitochondria in the presence or absence of a membrane potential. Following 
import, mitochondria were osmotically ruptured, treated with trypsin, resolved by SDS-
PAGE, and bands detected by phosphoimaging. P, precursor (5% of precursor protein + 
100 μg mitochondria); p, precursor; m, mature. (H) The percentage of precursor imported 
at each time point was calculated (mean ± SEM; n = 3).  See also Fig. S1 and Table SI.
Figure 3. tazTALEN cells have altered mitochondrial CL and MLCL profiles as
determined by high-perfomance liquid chromatography-mass spectrometry. The 
relative amounts of CL (A), MLCL (B), and PG (D) was determined by high-
performance liquid chromatography-mass spectrometry. (C) The ratio of MLCL:CL as 
determined from (A and B). The abundance of CL (E) and MLCL (L) of a given acyl 
chain length (E,L) or containing the indicated number of double bonds (F, M), was 
determined as a percentage of the total amount of CL or MLCL. The distribution of 
double bonds per acyl chain length for CL (G-K) and MLCL (N-O) expressed as a 
percent of the sum of all species of the indicated length. All data are the mean ± SEM (n
= 3). Significant differences are indicated. See also Figures S2-S4. 
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Figure 4. Membrane association and assembly of TAZ. (A) Mitochondria were 
sonicated and equal volumes of the pellet (P) and TCA-precipitated supernatant (S) 
fractions were immunoblotted as indicated. SM, starting material. (B) Mitochondria were 
incubated in 0.1 M Na2CO3 of the listed pH. Integral proteins (P) were separated from 
released proteins (S) by ultracentrifugation and equal volumes of each were 
immunoblotted as indicated. (C) Quantified band intensities of the P and S fractions were 
plotted as the percentage of total protein released into the supernatant for each pH (mean 
± SEM; n = 3 (C109) or 4 (293)). (D) Mitochondria from control and BTHS fibroblasts 
(450 μg), 293 Flp-In cells (200 μg), and mouse heart and liver (200 μg) were solubilized 
with digitonin, separated by 2D BN/SDS-PAGE, and immunoblotted for TAZ.
Figure 5. Mammalian TAZ is protease resistant and associates with IMS-facing 
leaflets. (A) Mitochondria were titrated with increasing amounts of digitonin to 
differentially solubilize mitochondrial compartments. After centrifugation, equal volumes 
of the pellet (P) and supernatant (S) fractions were resolved by SDS-PAGE and 
immunoblotted. (B) Quantified band intensities for two markers per compartment were 
combined and plotted as the percent detected in supernatant (mean ± SEM; n = 7). (C) 
Mitochondria, osmotically ruptured mitoplasts, or detergent-solubilized mitochondria 
from the indicated source were incubated without or with protease, resolved by SDS-
PAGE, and immunoblotted. (D) Mitochondria were solubilized with 0.1% (v/v) SDS and
where indicated, heated at 95oC for 5 minutes prior to adding pronase E, proteinase K, or 
trypsin. Equal volumes of each sample were resolved by SDS-PAGE and immunoblotted. 
(E) Mitochondria were solubilized with digitonin and fractionated into a supernatant (S1) 
and pellet (P1) by centrifugation. Material not extracted by digitonin (P1) was further 
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solubilized with TX–100 and separated into a supernatant (S2) and pellet (P2) by 
centrifugation. Fractions were resolved by SDS–PAGE and immunoblotted as indicated. 
(F) In organello import of radiolabeled [35S]-TAZ into 293 Flp-In mitochondria at the 
indicated temperature in the presence or absence of a membrane potential. Following 
import, mitochondria were treated with trypsin, resolved by SDS-PAGE, and bands 
detected by phosphoimaging. Where indicated, mitochondria were osmotically ruptured 
in the presence or absence of trypsin. P, precursor (5% of precursor protein + 100 μg
mitochondria).  
Figure 6. Both termini of TAZ are in the IMS. (A) Cartoon of epitope tagged TAZ 
constructs. (B) Whole cell extracts (30 μg) were immunoblotted for the indicated proteins. 
(C) Phospholipids from the indicated cells were labeled with 32Pi and separated by TLC. 
(D) Quantification of the MLCL:CL ratio (mean ± SEM; n=3). Significant differences 
compared to WT 293 Flp-In cells were determined by one-way ANOVA. n.s. = 
differences not significant. (E and F) The protease accessibility of epitope tags added to 
the NH2 (E) or COOH (F) termini of TAZ was determined as in Fig. 5C. (G) tazTALEN.19 
cells overexpressing WT or TAZ-APEX2 were labeled in vivo with H2O2 and DAB 
followed by OsO4 and EM imaging. Scale bars are provided in each panel. 
Figure 7. The R57L allele is highly unstable. (A) Sequence alignment of TAZ from the 
indicated species encompassing human Arg57 and His69 (white face on black 
background) and the HXXXXD motif (underlined). (B) Whole cell extracts (20 μg) from 
5-6 clones transfected with the indicated TAZ alleles were immunoblotted. (C) Relative 
mRNA level of TAZ analyzed by the comparative CT (ΔΔCT) method, represented as 
mean fold change (2ΔΔCT) ± SD n ≥ 4 relative to 293 Flp-In TAZ expression. (D) In
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organello import of radiolabeled precursor R57L TAZ into freshly isolated 293 Flp-In 
mitochondria as described in Fig. 5F. (E) tazTALEN cells overexpressing WT, R57L and 
H69Q alleles were incubated for 4 hours with 20 μM of the proteasome inhibitor, MG132. 
40 μg of whole cell lysates were resolved by SDS-PAGE and immunoblotted for the 
indicated proteins. (F) Whole cell extracts (20 μg) were collected after incubation with 
cycloheximide for the indicated times, and the amount of TAZ remaining assessed by 
immunoblot. The half-lives of the indicated TAZ alleles were calculated using the mean 
of five individual repetitions. See also Fig. S5.
Figure 8. The H69Q mutant is catalytically dead. (A) Mitochondria (20 μg) from 293 
Flp-In, tazTALEN, and tazTALEN cells overexpressing WT, R57L and H69Q alleles were 
immunoblotted as indicated. (B) In organello import of radiolabeled precursor H69Q 
TAZ into freshly isolated 293 Flp-In mitochondria as described in Fig. 5F. (C) Assembly 
of H69Q as determined by 2D BN/SDS-PAGE. (D) Lyso-PC to PC transacylase activities 
were determined in mitochondria isolated from 293 Flp-In, tazTALEN, and tazTALEN cells 
overexpressing the indicated TAZ alleles (mean ± SEM, n = 3). Significant differences 
are indicated. n.s., not significant. The relative amounts of CL (E) and MLCL (F), and the 
subsequent MLCL:CL ratio (G), in tazTALEN cells overexpressing WT, R57L, and H69Q 
were determined as previously described. See also Fig. S5. 
ABBREVIATIONS  
BTHS, Barth syndrome; CL, cardiolipin; IMM, inner mitochondrial membrane; IMS, 
intermembrane space; MLCL, monolysocardiolipin; LOF, loss-of-function; mAb, 
monoclonal antibody; OMM, outer mitochondrial membrane; OXPHOS, oxidative 
phosphorylation; PC, phosphatidylcholine; PG, phosphatidylglycerol.  
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